Half Year 2025 argenx SE Earnings Call Transcript
Key Points
- argenx SE (ARGNF) reported a 97% year-over-year growth in VYVGART sales, demonstrating strong market demand.
- The company has successfully initiated multiple registrational trials in large market opportunities such as Sjögren's, myositis, and TED.
- argenx SE (ARGNF) has advanced four new molecules into its pipeline, indicating robust R&D progress.
- The introduction of the prefilled syringe for VYVGART has driven new patient starts and increased prescriber demand.
- The company maintains a strong financial position with a cash balance of $3.9 billion, up from $3.4 billion at the beginning of the year.
- The gross to net adjustments increased from 12% to approximately 20%, impacting revenue calculations.
- Supply to China showed no growth, reflecting dependency on shipment timing rather than demand.
- Operating expenses increased by $98 million compared to Q1, driven by higher SG&A and R&D costs.
- The cost of sales for the quarter was $111 million, leading to a year-to-date gross margin of only 11%.
- The company faces increasing competition in the MG market, particularly from new entrants like UPLIZNA.
Good morning. My name is Rob, and I will be your conference operator today. I would like to welcome everyone to the call. (Operator Instructions) I'd now like to introduce Beth DelGiacco, Vice President, Corporate Communications and Investor Relations. You may begin your call.
Thank you. A press release was issued earlier today with our half-year 2025 financial results and second-quarter business update. This can be found on our website along with the presentation for today's webcast. Before we begin, on slide 2, I'd like to remind you that forward-looking statements may be presented during this call. These may include statements about our future expectations, clinical developments, regulatory timelines, the potential success of our product candidates, financial projections and upcoming milestones.
Actual results may differ materially from those indicated by these statements. Argenx is not under any obligation to update statements regarding the future or to
| Access to All Earning Calls and Stock Analysis | |
| 30-Year Financial on one screen | |
| All-in-one Stock Screener with unlimited filters | |
| Customizable Stock Dashboard | |
| Real Time Insider Trading Transactions | |
| 8,000+ Institutional investors’ 13F holdings | |
| Powerful Excel Add-in and Google sheets Add-on | |
| All data downloadable | |
| Quick customer support | |
| And much more... |
Trustpilot
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
